Hikma Pharmaceuticals (OTCMKTS:HKMPF) Rating Increased to Hold at Barclays

Hikma Pharmaceuticals (OTCMKTS:HKMPF) was upgraded by Barclays from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday, Zacks reports.

Separately, Citigroup reissued a “buy” rating on shares of Hikma Pharmaceuticals in a report on Wednesday, August 12th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Moderate Buy”.

Hikma Pharmaceuticals Stock Performance

OTCMKTS:HKMPF opened at $22.19 on Tuesday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.06 and a current ratio of 1.82. The stock’s 50 day moving average price is $21.52 and its two-hundred day moving average price is $19.63. Hikma Pharmaceuticals has a 12-month low of $16.34 and a 12-month high of $25.34.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.